First in Human and Early Stage Clinical Trials of Novel Investigational Drugs or Neuromodulatory Device-based Interventions for Psychiatric Disorders (U01 Clinical Trial Required)
Grants.gov PAR-25-180 · HHS-NIH11
| Funder | National Institutes of Health |
|---|---|
| Status | open |
| Opens | 26 Nov 2024 |
| Deadline | 15 Oct 2027 — 350 days |
| Action | posted |
| Official page | https://www.grants.gov/search-results-detail/357424… |
| Last checked | 2026-10-30 06:02:42+00:00 |
Exclusions found in the call's own text
You are reading one call. 1,058 are open right now.
A search matches words. It cannot know what your institution works on. Give the name and every open call is ranked against it — this one included.
This call page is free · no account · the report arrives by emailScope
The purpose of this Notice of Funding Opportunity (NOFO) is to encourage cooperative agreement applications to support early stage clinical trials of novel mechanism of action, investigational drugs, or novel neuromodulatory devices for the treatment of psychiatric disorders in areas of unmet medical need. The NOFO will support milestone-driven early stage trials in pediatric and adult populations. First in human (FIH) and Phase II studies of novel agents must assess target engagement (brain exposure), pharmacological effects, safety, and tolerability to assess feasibility for Phase II/proof of concept (PoC) studies in psychiatric disorders. Phase II/PoC studies must evaluate the drugs impact on clinically relevant physiological systems (functional measures) and clinical indicators of effect. The NOFO also supports FIH and early feasibility studies (EFS) of novel devices to evaluate target engagement, safety, tolerability, and efficacy. The overall objective is to facilitate rapid collection of data to "de-risk" novel mechanism of action investigational drugs, novel drugs for use in pediatric populations with psychiatric disorders, and devices or combination treatments in order to attract private or other public funding for further clinical development as FDA-approved treatments. A key aspect of this NOFO is the formation of collaborative partnerships between the biomedical researchers and biotechnology or industry researchers to facilitate psychiatric drug or device development.
Get told when something changes
Most institutions find out about a call with three weeks left. We write when something opens, moves or closes that fits what you work on, with the deadline, the fit and the funder's own exclusion clauses quoted. Nothing in a quiet week. Free, and one click to leave.
Starting from the programme you are reading: HHS-NIH11 — change it below if you like.
Leave the second box empty and you get whatever opened or changed recently, closing soonest. Fill it in and it ranks against your words instead: that is the difference between a list and a shortlist.
Scientific Network Management will send you the current list for these terms, and after that only what changes: a call that opens, a deadline that shifts, a clause that rules you out. Nothing is sent when nothing has moved. One click to stop, in every message.
One confirmation email and nothing else until you click it. No tracking pixels, no sharing, one click to unsubscribe.
Of every 100 Horizon Europe proposals
A funding strategy reads your institution's own published record against the calls that are open, and says in writing which are worth the year and which to decline, with the reason for each.
Scientific Network Management, the grant-writing practice behind this radar: 13 years of EU-funded research projects, and a founder who has served as Key Expert and Team Leader on two EU-funded technical assistance contracts establishing biotechnology centres in Türkiye.
SNM also does
No obligation, and nothing here is conditional on using us: searching the calls stays free and asks for nothing either way.